Expert Review of Clinical Immunology最新文献_第2页

Predicting worsening risk in MGFA class I, II and III myasthenia gravis patients: development and validation of a predictive nomogram. 预测MGFA I、II和III级重症肌无力患者恶化的风险：一种预测图的开发和验证

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-30 DOI: 10.1080/1744666X.2025.2494653

Seoyeong Pang, Yanyuan Du, Siyang Peng, Linghao Meng, Anni Xiong, Wenzeng Zhu

{"title":"Predicting worsening risk in MGFA class I, II and III myasthenia gravis patients: development and validation of a predictive nomogram.","authors":"Seoyeong Pang, Yanyuan Du, Siyang Peng, Linghao Meng, Anni Xiong, Wenzeng Zhu","doi":"10.1080/1744666X.2025.2494653","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2494653","url":null,"abstract":"Background: Myasthenia gravis (MG), a neuromuscular junction autoimmune disorder, causes skeletal muscle weakness. MG worsening frequently occurs during the disease course, severely impairing quality of life and elevating myasthenic crisis risk. Existing predictive models remain scarce. This study developed a predictive model for MG worsening to facilitate early risk stratification and personalized care.Research design & methods: Retrospective analysis included 437 the Myasthenia Gravis Foundation of America (MGFA) class I - III myasthenia gravis patients from December 2019 to September 2024. Sociodemographic, clinical variables and worsening status were analyzed. Predictors were identified via univariate analysis, the Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate logistic regression. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis.Results: Patients were randomized into training (n = 305) and validation (n = 132) cohorts. Worsening rates were comparable (26.52% vs. 31.15%, p = 0.331). Six predictors emerged: age, MGFA classification, thymectomy history, chills, fatigue, and emotional disturbances (ED). The nomogram demonstrated strong discrimination (AUC: 0.82 training, 0.83 validation) and calibration (Hosmer-Lemeshow p > 0.05). Decision curve analysis confirmed clinical utility at 10-70% probability thresholds.Conclusion: This nomogram integrates accessible clinical variables to stratify MG worsening risk, enabling early intervention. Validation through multicenter prospective studies is warranted to optimize generalizability.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individual differences in response to dust-mite-allergen specific immunotherapy in allergic rhinitis: a meta-analysis of randomized controlled trials. 变应性鼻炎对尘螨过敏原特异性免疫治疗反应的个体差异：随机对照试验的荟萃分析。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-29 DOI: 10.1080/1744666X.2025.2499596

Dandan Fang, Jiajia Wang, Jingyun Li, Luo Zhang, Yuan Zhang

{"title":"Individual differences in response to dust-mite-allergen specific immunotherapy in allergic rhinitis: a meta-analysis of randomized controlled trials.","authors":"Dandan Fang, Jiajia Wang, Jingyun Li, Luo Zhang, Yuan Zhang","doi":"10.1080/1744666X.2025.2499596","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2499596","url":null,"abstract":"Introduction: The variability in the efficacy of allergen-specific immunotherapy (AIT) for nasal symptom control can be attributed to individual differences, to explore the hypothesis of systematic variability in AR symptom alleviation with AIT and to determine whether this variability correlates with AR severity, route of administration, treatment duration, age, or study publication year.Methods: We reviewed randomized controlled trials (RCTs) of AIT for dust mite (DM)-induced AR, extracting data on baseline mean, endpoint mean, standard deviation (SD), and participant numbers. A random-slope mixed-effects model (RSMM) was employed to evaluate the differences in variability between the AIT and control groups, as well as to identify potential influencing factors.Results: There was no significant difference in response variability between the AIT and control groups. The response variability to AIT was not associated with AR severity, route of administration, age, or year of publication. The cohort that underwent 36 months of AIT exhibited a higher degree of response variability compared to the group treated for 6 months.Conclusion: The present study did not identify systematic variability in individual response to AIT when measured by TNSS alone. More refined outcome measures and more associated factors are needed to explore personalized AIT in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular endothelial growth factors in airway allergic diseases: pathophysiological functions and therapeutic prospects. 血管内皮生长因子在气道变应性疾病中的病理生理功能及治疗前景。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-28 DOI: 10.1080/1744666X.2025.2499597

Yu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang

{"title":"Vascular endothelial growth factors in airway allergic diseases: pathophysiological functions and therapeutic prospects.","authors":"Yu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang","doi":"10.1080/1744666X.2025.2499597","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2499597","url":null,"abstract":"Introduction: Vascular endothelial growth factors (VEGFs) play a crucial role in regulating physiological angiogenesis and homeostasis during growth and development. Recent advancements in our knowledge of VEGFs have revealed their complex role in coordinating vascular homeostasis and pathological role in various airway allergic reactions and structural remodeling, especially in allergic asthma and allergic rhinitis (AR), which has become more apparent.Areas covered: After an extensive search of PubMed and Web of Science databases, our review covered articles published from 1989 to 2024. The purpose of this review was to review previous studies on VEGFs involved in inflammatory progression and tissue remodeling in airway allergic diseases, to summarize the relevant pathways. This article further reviews that VEGFs and their receptors can also be potential targets for treating airway allergic diseases.Expert opinion: The prevalence of airway allergic diseases is increasing, which has caused a serious economic burden. VEGFs and their receptors have been recognized as potential targets for therapeutic interventions, which have been effectively applied in the treatment of tumors and other diseases. Fully elucidating the involvement of VEGFs in the disease process will help us understand their mechanisms of action and develop targeted therapies for allergic diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the ubiquitin-proteasome pathway in systemic lupus erythematosus. 靶向系统性红斑狼疮的泛素-蛋白酶体途径。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-24 DOI: 10.1080/1744666X.2025.2497845

Chi Chiu Mok

{"title":"Targeting the ubiquitin-proteasome pathway in systemic lupus erythematosus.","authors":"Chi Chiu Mok","doi":"10.1080/1744666X.2025.2497845","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2497845","url":null,"abstract":"Introduction: The ubiquitin-proteasome system (UPS) is the major non-lysosomal mechanism for selective degradation of intracellular proteins that is essential for the regulation of cellular functions and survival. Modulation of the proteasomes and cereblon E3 ligase promotes degradation of polyubiquitin-tagged transcription factors and oncoproteins, leading to depletion of long-lived plasma cells, diminished autoantibody and interferon-α production, reduced T-cell polarization to the proinflammatory phenotypes and increased regulatory T-cell activity that are relevant to the therapy of systemic lupus erythematosus (SLE).Areas covered: Selective immunoproteasome inhibitors and newer generation cereblon modulators have improved safety profiles compared to conventional compounds. This article summarizes the literature regarding the modulation of the UPS in murine and human SLE.Expert opinion: Bortezomib and the selective immunoproteasome inhibitors, ONX-0914 and zetomipzomib, ameliorate renal disease in murine lupus models. While clinically effective in refractory SLE, bortezomib is limited by its toxicities. Zetomipzomib shows promising data in phase Ib/II studies of SLE and lupus nephritis. Thalidomide and lenalidomide are effective in refractory cutaneous lupus but again limited by their off-target effects. A phase II RCT of iberdomide shows favorable results in SLE, especially chronic and subacute cutaneous lesions. These molecules should be further explored in larger clinical trials of renal and cutaneous SLE.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The therapeutic effect of mRNA vaccines in glioma: a comprehensive review. mRNA疫苗治疗胶质瘤的疗效综述

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-22 DOI: 10.1080/1744666X.2025.2494656

Fatemeh Afrashteh, Simin Seyedpour, Nima Rezaei

{"title":"The therapeutic effect of mRNA vaccines in glioma: a comprehensive review.","authors":"Fatemeh Afrashteh, Simin Seyedpour, Nima Rezaei","doi":"10.1080/1744666X.2025.2494656","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2494656","url":null,"abstract":"Introduction: Glioma is the most common primary brain tumor, with glioblastoma being the most lethal type due to its heterogeneous and invasive nature of the cancer. Current therapies have low curative success and are limited to surgery, radiotherapy, and chemotherapy. More than 50% of patients become resistant to chemotherapy, and tumor recurrence occurs in most patients following an initial course of therapy. Therefore, developing novel, effective strategies for glioma treatment is essential. Cancer vaccines are novel therapies that demonstrate advantages over conventional methods and, therefore, may be promising options for treating glioma.Areas covered: This article provided a critical review of pre-clinical and clinical studies that explored appropriate tumor antigen candidates for developing mRNA vaccines and discussed their clinical application in glioma patients. Medline database, PubMed, and ClinicalTrials.gov were searched for glioma vaccine studies published before 2025 using related keywords.Expert opinion: mRNA vaccines are promising strategies for treating glioma because they are efficient, cost-beneficial, and have lower side effects than other types such as peptide or DNA-based vaccines.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-13"},"PeriodicalIF":3.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of peripheral neuropathy in Egyptian Psoriatic Arthritis Patients and its correlation with disease activity. 埃及银屑病关节炎患者周围神经病变的患病率及其与疾病活动度的相关性

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-21 DOI: 10.1080/1744666X.2025.2495170

MennaAllah Mohamed Ali Elmalla, Hanaa Ahmad Samy Elbanna, Manal Shawky Hussein Sayed Ahmed, Amira Mohamed El Sharkawy

{"title":"Prevalence of peripheral neuropathy in Egyptian Psoriatic Arthritis Patients and its correlation with disease activity.","authors":"MennaAllah Mohamed Ali Elmalla, Hanaa Ahmad Samy Elbanna, Manal Shawky Hussein Sayed Ahmed, Amira Mohamed El Sharkawy","doi":"10.1080/1744666X.2025.2495170","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2495170","url":null,"abstract":"Introduction: Peripheral neuropathy (PN) may arise from various etiologies, including immune-mediated diseases.This study aimed to detect the prevalence and clinical determinants of PN in psoriatic arthritis (PsA) patients, with or without skin lesions, and to evaluate its correlation with disease activity.Research design and methods: This cross sectional study included 60 PsA patients and 60 apparently healthy controls. Neuropathic pain was evaluated using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score, while PN was assessed through the Michigan Neuropathy Screening Instrument (MNSI), in conjunction with electrophysiological assessment.Results: The LANSS score demonstrated the capability to predict neuropathic pain in PsA patients with a sensitivity of 93.89% and specificity of 83.33%. Furthermore, the MNSI Questionnaire score revealed a sensitivity of 91.67% and specificity of 77.78% in predicting PN among PsA patients. Carpal tunnel syndrome represented the most prevalent neuropathy identified in 36% of PsA patients, followed by peripheral polyneuropathy in 6%, and ulnar neuropathy in 4%.Conclusions: Patients with PsA have higher prevalence of neuropathy, particularly carpal tunnel syndrome, which negatively impacts pain perception, functional capability, and quality of life, particularly in those with higher disease activity suggesting potential association between inflammation and neurological dysfunction.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucocorticoid in systemic lupus erythematosus: the art beyond science. 系统性红斑狼疮的糖皮质激素：超越科学的艺术。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-18 DOI: 10.1080/1744666X.2025.2494654

Tsz Ching Mok, Chi Chiu Mok

{"title":"Glucocorticoid in systemic lupus erythematosus: the art beyond science.","authors":"Tsz Ching Mok, Chi Chiu Mok","doi":"10.1080/1744666X.2025.2494654","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2494654","url":null,"abstract":"Introduction: Glucocorticoid (GC) remains the main stay of treatment for systemic lupus erythematosus (SLE) but is associated with a myriad of untoward effects. On the other hand, withdrawal of maintenance immunosuppression, including low-dose GCs, carries a risk of SLE flare.Areas covered: The molecular mechanisms of GCs and their implications for dosing strategies in clinical practice are discussed. Evidence regarding withdrawal of maintenance immunosuppression in SLE is reviewed.Expert opinions: The initial GC regimens for different manifestations of SLE are heterogeneous, with no major randomized controlled trials (RCTs) on their efficacy and toxicities available. RCTs on withdrawal of immunosuppressive drugs in quiescent SLE are inconsistent but appear to show an increase in disease flares, with risk factors being younger age, renal disease, cessation of hydroxychloroquine, shorter duration of remission, serological activity, and an abrupt tapering regime. The lowest effective doses of GC and immunosuppressive drugs should be adopted, and the decision to withdraw immunosuppression should be individualized. Newer strategies for GC sparing, including combination therapy of immunosuppressive and biological/targeted agents, and the use of methylprednisolone pulses for initial therapy of less serious manifestations of SLE, could ameliorate the toxicities of immunosuppression and help advance to the ultimate target of drug-free remission.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":3.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of severe asthma in children: current insights and future directions. 儿童严重哮喘的管理：当前的见解和未来的方向。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-15 DOI: 10.1080/1744666X.2025.2493698

Maria De Filippo, Riccardo Castagnoli, Ilaria Brambilla, Maddalena Leone, Gian Luigi Marseglia, Amelia Licari

{"title":"Management of severe asthma in children: current insights and future directions.","authors":"Maria De Filippo, Riccardo Castagnoli, Ilaria Brambilla, Maddalena Leone, Gian Luigi Marseglia, Amelia Licari","doi":"10.1080/1744666X.2025.2493698","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2493698","url":null,"abstract":"Introduction: Severe pediatric asthma represents a critical challenge in respiratory medicine, affecting a small but significant subset of children with disproportionate morbidity and healthcare burden. Its complexity arises from diverse phenotypes, endotypes, and inflammatory pathways that complicate diagnosis and management. Recent advances in precision medicine, particularly biologic therapies targeting Type 2 inflammation, offer new opportunities for improved outcomes.Areas covered: This review synthesizes current knowledge on severe pediatric asthma, emphasizing the pathophysiology, clinical phenotypes, and therapeutic advancements. It explores the role of biomarkers and endotypes in guiding personalized therapy and critically examines challenges such as non-Type 2 inflammation, barriers to biologic access, and variability in treatment response. A comprehensive literature search was conducted, focusing on biologic therapies, diagnostic innovations, and emerging care models.Expert opinion: Despite progress, challenges remain in achieving standardized treatment response definitions, validating biomarkers, and addressing cost barriers. Early biologic initiation in high-risk children and multidisciplinary care are critical to advancing outcomes. Future efforts should prioritize predictive algorithms, innovative therapies, and equitable access to shift from symptom control to disease prevention, potentially redefining the pediatric asthma care paradigm.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-15"},"PeriodicalIF":3.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential risk of autoimmune disorders in non-traumatic osteonecrosis: clue to pathogenesis. 非外伤性骨坏死中自身免疫性疾病的不同风险：发病机制的线索。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-03-05 DOI: 10.1080/1744666X.2025.2475982

Edward Y Cheng, Alireza Mirzaei

{"title":"Differential risk of autoimmune disorders in non-traumatic osteonecrosis: clue to pathogenesis.","authors":"Edward Y Cheng, Alireza Mirzaei","doi":"10.1080/1744666X.2025.2475982","DOIUrl":"10.1080/1744666X.2025.2475982","url":null,"abstract":"Introduction: Non-traumatic osteonecrosis is a frequent complication in patients with autoimmune disorders, though its prevalence varies markedly depending upon the type of disorder. Understanding the causes of this difference can help uncover the underlying pathophysiology of osteonecrosis and guide the development of effective preventive and therapeutic strategies.Areas covered: In this perspective study, we reviewed available databases, including PubMed, Cochrane Library, Scopus, and Web of Science, to explore why the risk of osteonecrosis varies among different autoimmune disorders. Is this variation primarily due to the disease's pathophysiology, the use of medications such as corticosteroids, or a combination of both? If both factors are involved, what is the extent of each contribution in this context?Expert opinion: Non-traumatic osteonecrosis is often induced by an interaction between disease pathophysiology and corticosteroid use. In patients with different autoimmune disorders but an identical history of corticosteroid use, the risk of osteonecrosis is influenced by how the underlying pathophysiology compromises bone health. In autoimmune disorders with multiple adverse effects on bone, such as SLE (systemic lupus erythematosus), there is a much higher risk of osteonecrosis compared to disorders with minimal impact on bone health, such as celiac disease and MS (multiple sclerosis).","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"413-424"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic methods and strategies for autoimmune bullous diseases. 自身免疫性大疱性疾病的诊断方法和策略。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-04-01 Epub Date: 2025-02-17 DOI: 10.1080/1744666X.2025.2465405

Hua Qian, Norito Ishii, Hiroshi Koga, Kwesi Teye, Atsunari Tsuchisaka, Takekuni Nakama, Chiharu Tateishi, Mako Mine, Daisuke Tsuruta, Yoshiaki Hirako, Xiaoguang Li, Takashi Hashimoto

{"title":"Diagnostic methods and strategies for autoimmune bullous diseases.","authors":"Hua Qian, Norito Ishii, Hiroshi Koga, Kwesi Teye, Atsunari Tsuchisaka, Takekuni Nakama, Chiharu Tateishi, Mako Mine, Daisuke Tsuruta, Yoshiaki Hirako, Xiaoguang Li, Takashi Hashimoto","doi":"10.1080/1744666X.2025.2465405","DOIUrl":"10.1080/1744666X.2025.2465405","url":null,"abstract":"Introduction: Autoimmune bullous disease (AIBD), showing blistering lesions on the skin and/or mucous membranes, is characterized by autoantibodies against various structural molecules present in keratinocyte cell surfaces and epidermal basement membrane zone. In addition to the clinical and pathological features, identification of specific autoantibodies is essential for AIBD diagnosis, and therefore corresponding methods should be well summarized and popularized.Area covered: Currently, direct immunofluorescence using biopsy tissue specimen and indirect immunofluorescence using normal human skin, 1 M NaCl-split skin and rat bladder are primarily used to identify tissue-bound and circulating autoantibodies, respectively. Immunoblotting and enzyme-linked immunosorbent assay (ELISA) methods have been developed for detection of autoantibodies against AIBD autoantigens, including desmoglein 1, desmoglein 3, BP180, BP230, type VII collagen, laminin (LM) 332, integrin α6β4, p200 (LMγ1/LMβ4) and human serum albumin. In this review, we summarized the detailed laboratory protocols for AIBD diagnosis methods used in our three institutes (Kurume University and Osaka Metropolitan University in Japan, and Daqing Oilfield General Hospital in China) before 9 October 2024.Expert opinion: This review will benefit both clinical practitioners and basic researchers on AIBD. In the future, simpler and easier AIBD diagnostic algorithms using a smaller number of tests should be established.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"451-460"},"PeriodicalIF":3.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0